SYN-004 Safety and Tolerability in Allo-HCT Subjects
Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
Sponsor: Theriva Biologics, Inc.
A PHASE1/PHASE2 clinical study on Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant and Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics, this trial is ongoing. The trial is conducted by Theriva Biologics, Inc. and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 6 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Theriva Biologics, Inc.
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .